title: Effective hemostasis with rFVIIa treatment in two patients with severe thrombocytopenia and life-threatening hemorrhage.
abstract: We report two patients with severe thrombocytopenia and life-threatening bleeding that were successfully managed with recombinant activated factor VII (rFVIIa). The first was a 75-year-old male with Waldenström's macroglobulinemia. During a therapeutic course with fludarabine, he developed severe autoimmune thrombocytopenia resistant to conventional treatment, followed by persistent uncontrollable nasal bleeding. Platelet transfusions failed to increase the platelet count and control the hemorrhage. When hemoglobin levels fell below 8.5 g/dL and the patient's clinical condition got much worse, a single dose of 4.8 mg rFVIIa (90 microg/kg) was given as an i.v. bolus. Ten minutes after the rFVIIa injection, nasal bleeding stopped, the patient's clinical condition progressively improved, and splenectomy could be carried out uneventfully 2 days later. The second patient, a 52-year-old female, was under treatment for pre-B lymphoblastic leukemia. She developed severe thrombocytopenia, secondary to chemotherapy, complicated by massive gastrointestinal bleeding. Despite intensive treatment with platelet transfusions, hemorrhage continued and her condition deteriorated rapidly. She was then given an i.v. bolus injection of 4.8 mg rFVIIa, which resulted in cessation of hemorrhage and dramatic improvement of her clinical status. No adverse effects from the treatment with rFVIIa were observed. In conclusion, rFVIIa appears to be an attractive alternative for controlling hemorrhage in patients with severe thrombocytopenia, especially when platelet transfusions are unavailable or ineffective.
authors.affiliation: Department of Hematology, Theagenio Cancer Hospital, Thessaloniki, Greece. gerotziafasgrigoris@hotmail.com
authors.forename: Grigoris T
authors.initials: GT
authors.lastname: Gerotziafas
authors.forename: Costas
authors.initials: C
authors.lastname: Zervas
authors.forename: George
authors.initials: G
authors.lastname: Gavrielidis
authors.forename: Aggelos
authors.initials: A
authors.lastname: Tokmaktsis
authors.forename: Evdoxia
authors.initials: E
authors.lastname: Hatjiharissi
authors.forename: Mary
authors.initials: M
authors.lastname: Papaioannou
authors.forename: Anna
authors.initials: A
authors.lastname: Lazaridou
authors.forename: Nikos
authors.initials: N
authors.lastname: Constantinou
authors.forename: Meyer Michel
authors.initials: MM
authors.lastname: Samama
authors.forename: John
authors.initials: J
authors.lastname: Christakis
mesh_terms: D000368:Aged; D016638:Critical Illness; D015942:Factor VIIa / Q000008:administration & dosage*; D005260:Female; D006470:Hemorrhage / Q000188:drug therapy*; D006487:Hemostasis / Q000187:drug effects*; D006801:Humans; D007275:Injections, Intravenous; D008297:Male; D008875:Middle Aged; D009503:Neutropenia / Q000150:complications; D015452:Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / Q000097:blood / Q000150:complications / Q000188:drug therapy; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000627:therapeutic use; D013921:Thrombocytopenia / Q000097:blood / Q000139:chemically induced / Q000188:drug therapy*; D008258:Waldenstrom Macroglobulinemia / Q000097:blood / Q000150:complications / Q000188:drug therapy
chemical_list: D011994:Recombinant Proteins; D015942:Factor VIIa